Abstract
It’s not Seagen but another company that Merck & Co. will acquire this year. The pharma giant will pay a total of $1.35 billion for Imago BioSciences. Merck’s acquisition of Imago strengthens the larger firm’s presence in hematology, says Hugh Y. Rienhoff Jr., Imago’s founder and CEO. Last year, Merck bought Acceleron Pharma for $11.5 billion to obtain the fusion-protein drug sotatercept, which recently aced its Phase 3 trials to treat pulmonary arterial hypertension. Earlier this year, Merck made plans to snap up Seagen—a purchase that would have been its largest in a decade. But the negotiations reportedly stalled over pricing. Imago aims to treat blood diseases such as myeloproliferative neoplasms; they are characterized by an overproduction of blood cells, which may result in clots that cause stroke or heart attacks. Imago went public last year. Its lead asset is bomedemstat, an inhibitor of lysine-specific demethylase 1 (LSD1) . LSD1
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
